Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,828 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04095351Recruiting
Study of connective tissue disease affecting the lungs
This study looks at people aged 18 and older who have a connective tissue disease and lung involvement. It aims to better understand how these lung problems progress and may help doctors choose better care.
InnsbruckAges 18–80 - NCT04026360Recruiting
Study early lung, virus, and gut changes in children with cystic fibrosis
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
BernAges birth–18 years - NCT04829708RecruitingPhase 3
Preventing brain spread in limited-stage small cell lung cancer
This trial compares two ways to manage limited-stage small cell lung cancer that has improved after initial chemotherapy and radiation. Participants will either get preventive brain radiation or have regular brain MRI scans instead, to see which approach is safer and works better.
Jinan, ShandongAges 18–75 - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT05053802RecruitingPhase 2
Microwave tumor ablation plus immunotherapy for multiple lung cancers
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT05104788RecruitingPhase 2
Icotinib plus chemotherapy before surgery for EGFR lung cancer
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
BeijingAges 18–75 - NCT05270616Recruiting
Robotic or video-assisted lung surgery compared
This trial compares robotic surgery and video-assisted surgery for removing part of the lung (lobectomy or segmentectomy). It may help determine which approach is safer or works better for patients who can safely tolerate minimally invasive surgery.
Jinan, ShandongAges 18–85 - NCT04976296Recruiting
Monitoring minimal residual disease after lung cancer surgery
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
Guangzhou, GuangdongAges 18 years+ - NCT05365009Recruiting
Autoimmune lung scarring registry for adults with recent diagnosis
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
Buenos AiresAges 18 years+ - NCT05391100Recruiting
Screening people with rheumatoid arthritis for lung scarring
This study looks for early lung scarring in people who have rheumatoid arthritis. It may help find a serious lung condition earlier so doctors can watch or treat it sooner.
BudapestAges 40 years+ - NCT04951635RecruitingPhase 3
Almonertinib after chemoradiation for stage III lung cancer
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Ji'nan, ShandongAges 18 years+ - NCT05426135Recruiting
AI tool to assess cancer risk and guide care
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
Wuhan, HubeiAges 18–75 - NCT05469022RecruitingPhase 2
Lazertinib before lung surgery for EGFR-mutant lung cancer
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
SeoulAges 19 years+ - NCT05494021Recruiting
Lung cancer screening study for higher-risk adults
This study tests whether people at higher risk for lung cancer can be safely screened using regular chest CT scans. You might benefit from closer monitoring, and the study helps doctors learn the best way to catch lung cancer earlier.
Shanghai, Shanghai MunicipalityAges 45–75 - NCT02852928Recruiting
ChILD-EU registry for childhood lung disease samples
This trial builds a European “registry and biobank” of children with suspected or confirmed interstitial lung disease (a type of lung problem), as well as conditions that can look similar. It helps researchers learn more about these rare childhood lung diseases and connect families to future studies.
Hanover, Lower SaxonyAges Any age - NCT05636605Recruiting
Study lung cancer biology and why immunotherapy stops working
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Yiwu, ZhejiangAges 18–80 - NCT05797493Recruiting
Test blood and immune markers in extensive-stage small cell lung cancer
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
RomeAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02448992RecruitingPhase 2/Phase 3
Brain radiation that avoids the memory area in lung cancer
This trial studies a “prophylactic” (preventive) type of brain radiation for people with lung cancer that has spread to nearby lymph nodes but not to the brain. It aims to lower the chance of brain metastases while protecting the hippocampus, an area linked to memory.
TaoyuanAges 18–80 - NCT04539977RecruitingPhase 2
PD-L1 antibody plus chemotherapy for limited-stage small-cell lung cancer
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05778708Recruiting
Tai Chi and aerobic exercise for mood and sleep in late lung cancer
This study tests whether Tai Chi and aerobic exercise can improve clusters of emotional symptoms—like anxiety, low mood, poor sleep, and fatigue—in people with late-stage non-small cell lung cancer. If you have these symptoms and are not already doing regular exercise programs, the trial may offer a structured way to feel better.
Hong KongAges 18 years+ - NCT04741711Recruiting
At-home ultrasound to help manage heart failure
This study tests whether using lung ultrasound at regular visits can help guide care for people with heart failure. It may help doctors spot worsening fluid problems earlier, before symptoms become severe.
BesançonAges 18 years+ - NCT05663242RecruitingPhase 4
Comparing anesthetics for outcomes after lung tumor surgery
This study looks at whether using different anesthesia drugs during planned lung tumor surgery affects recovery and longer-term outcomes. It also aims to understand why the anesthesia choice might make a difference.
Kaohsiung CityAges 20–80 - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,828 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.